However, a novel therapeutic gorilla adenovirus HPV vaccine, PRGN-2009, has shown promise when tested in PBMC-humanized NSG mice bearing human HPV16+ cervical tumors as it reduced tumor growth and increased CD8+ and CD4+ T cell levels in the TME, supporting its use in clinical trials (84) (Figure 2D). This evidence concerns the gene CD8A and neoplasm.